NO980881L - Fremgangsmater og blandinger for selektiv modifikasjon av nukleinsyrer - Google Patents

Fremgangsmater og blandinger for selektiv modifikasjon av nukleinsyrer

Info

Publication number
NO980881L
NO980881L NO19980881A NO980881A NO980881L NO 980881 L NO980881 L NO 980881L NO 19980881 A NO19980881 A NO 19980881A NO 980881 A NO980881 A NO 980881A NO 980881 L NO980881 L NO 980881L
Authority
NO
Norway
Prior art keywords
compositions
methods
nucleic acids
selective modification
inactivating
Prior art date
Application number
NO19980881A
Other languages
English (en)
Norwegian (no)
Other versions
NO980881D0 (no
Inventor
Edward I Budowsky
Original Assignee
Vi Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vi Technologies Inc filed Critical Vi Technologies Inc
Publication of NO980881D0 publication Critical patent/NO980881D0/no
Publication of NO980881L publication Critical patent/NO980881L/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0082Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using chemical substances
    • A61L2/0088Liquid substances
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/16Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using chemical substances
    • A61L2/18Liquid substances or solutions comprising solids or dissolved gases
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D203/00Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D203/00Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D203/04Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D203/06Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D203/08Heterocyclic compounds containing three-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring nitrogen atom
    • C07D203/12Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • C12N7/06Inactivation or attenuation by chemical treatment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00Reverse transcribing DNA viruses
    • C12N2730/00011Details
    • C12N2730/10011Hepadnaviridae
    • C12N2730/10111Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10161Methods of inactivation or attenuation
    • C12N2730/10163Methods of inactivation or attenuation by chemical treatment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00Reverse transcribing RNA viruses
    • C12N2740/00011Details
    • C12N2740/10011Retroviridae
    • C12N2740/16011Human Immunodeficiency Virus, HIV
    • C12N2740/16061Methods of inactivation or attenuation
    • C12N2740/16063Methods of inactivation or attenuation by chemical treatment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32411Hepatovirus, i.e. hepatitis A virus
    • C12N2770/32461Methods of inactivation or attenuation
    • C12N2770/32463Methods of inactivation or attenuation by chemical treatment
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2795/00Bacteriophages
    • C12N2795/00011Details
    • C12N2795/18011Details ssRNA Bacteriophages positive-sense
    • C12N2795/18111Leviviridae
    • C12N2795/18161Methods of inactivation or attenuation
    • C12N2795/18163Methods of inactivation or attenuation by chemical treatment
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)
NO19980881A 1995-08-29 1998-02-27 Fremgangsmater og blandinger for selektiv modifikasjon av nukleinsyrer NO980881L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/521,245 US6114108A (en) 1995-08-29 1995-08-29 Methods and compositions for the selective modification of viral nucleic acids
PCT/US1996/014040 WO1997007674A1 (en) 1995-08-29 1996-08-29 Methods and compositions for the selective modification of nucleic acids

Publications (2)

Publication Number Publication Date
NO980881D0 NO980881D0 (no) 1998-02-27
NO980881L true NO980881L (no) 1998-04-27

Family

ID=24075988

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19980881A NO980881L (no) 1995-08-29 1998-02-27 Fremgangsmater og blandinger for selektiv modifikasjon av nukleinsyrer

Country Status (18)

Country Link
US (1) US6114108A (zh)
EP (2) EP1129728B1 (zh)
JP (2) JP2001520635A (zh)
KR (1) KR100486765B1 (zh)
AT (2) ATE217144T1 (zh)
AU (1) AU694892B2 (zh)
BR (1) BR9610306A (zh)
CA (1) CA2230671A1 (zh)
DE (2) DE69635871T2 (zh)
DK (1) DK0915648T3 (zh)
ES (1) ES2173314T3 (zh)
HK (1) HK1042254A1 (zh)
IL (1) IL123467A0 (zh)
NO (1) NO980881L (zh)
NZ (1) NZ316787A (zh)
PL (1) PL187759B1 (zh)
PT (1) PT915648E (zh)
WO (1) WO1997007674A1 (zh)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5691132A (en) 1994-11-14 1997-11-25 Cerus Corporation Method for inactivating pathogens in red cell compositions using quinacrine mustard
US6177441B1 (en) 1995-06-05 2001-01-23 Cerus Corporation Treating red blood cell solutions with anti-viral agents
US6136586A (en) * 1995-08-29 2000-10-24 Vi Technologies, Inc. Methods for the selective modification of viral nucleic acids
US20040048235A1 (en) * 1995-08-29 2004-03-11 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US20040053208A1 (en) * 1995-08-29 2004-03-18 V. I. TECHNOLOGIES, Inc. Methods to selectively inactivate parasites in biological compositions
DE19633684A1 (de) * 1996-08-12 1998-02-19 Dirk Dipl Ing Vollenbroich Verfahren zur Inaktivierung von lipidumhüllten Viren
US6093725A (en) * 1997-01-06 2000-07-25 Cerus Corporation Frangible compounds for pathogen inactivation
US6514987B1 (en) 1997-01-06 2003-02-04 Cerus Corporation Frangible compounds for pathogen inactivation
US5891705A (en) * 1997-04-08 1999-04-06 Pentose Pharmaceuticals, Inc. Method for inactivating a virus
US6093564A (en) * 1997-10-03 2000-07-25 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
US6352695B1 (en) * 1997-10-03 2002-03-05 V.I. Technologies, Inc. Methods and compositions for the selective modification of nucleic acids
DE69826521T2 (de) 1998-01-06 2005-09-29 Cerus Corp., Concord Verfahren zum quenchen von pathogen-inaktivatoren in biologischen materialien
US6369048B1 (en) * 1998-01-12 2002-04-09 V.I. Technologies, Inc. Methods and compositions for inactivating viruses
AU4435399A (en) 1998-06-11 1999-12-30 Cerus Corporation Inhibiting proliferation of arterial smooth muscle cells
DE19827750C1 (de) * 1998-06-22 1999-07-29 Centeon Pharma Gmbh Verfahren zum Abtrennen von HIV aus einer Flüssigkeit
US6099734A (en) * 1998-07-08 2000-08-08 Baxter International Inc. Apparatus, membranes and methods for removing organic compounds from a biological fluid
US6908553B1 (en) 1998-07-08 2005-06-21 Baxter International Inc. Composite membrane with particulate matter substantially immobilized therein
DE19836559A1 (de) 1998-08-12 2000-03-23 Antigen Gmbh Gefäß zur Entnahme von Blut
US6403359B1 (en) 1998-09-25 2002-06-11 V. I. TECHNOLOGIES, Inc. Solid phase quenching systems
US6617100B2 (en) * 1998-09-25 2003-09-09 V.I. Technologies, Inc. Solid phase quenching systems
CA2345230A1 (en) * 1998-09-25 2000-04-06 V.I. Technologies, Inc. Methods to selectively inactivate viruses in biological compositions
US6150109A (en) 1999-01-25 2000-11-21 V. I. TECHNOLOGIES, Inc. Lipophilic quenching of viral inactivating agents
US9044523B2 (en) 2000-06-15 2015-06-02 Terumo Bct, Inc. Reduction of contaminants in blood and blood products using photosensitizers and peak wavelengths of light
WO2002055095A2 (en) * 2000-11-06 2002-07-18 Vi Technologies Inc Use of aziridino-compounds in the treatment of immune dysfunctions
US6602718B1 (en) 2000-11-08 2003-08-05 Becton, Dickinson And Company Method and device for collecting and stabilizing a biological sample
US20020131958A1 (en) * 2001-01-22 2002-09-19 John Chapman Method for purifying a biological composition
US6635679B2 (en) * 2001-05-14 2003-10-21 Akzo Nobel N.V. Methods and compositions for inactivating viruses
US20030127603A1 (en) * 2001-05-15 2003-07-10 Bernard Horowitz Apparatus for the inactivation of pathogens in protein-containing fluids and uses thereof
JP2005517023A (ja) * 2001-11-06 2005-06-09 ヴイ.アイ.テクノロジーズ,インコーポレーテッド アジリジン化合物の治療的使用
EP1459724B1 (en) 2001-12-28 2013-11-20 Terumo Kabushiki Kaisha Blood bag system and method of inactivating pathogenic microorganisms
US20050074743A1 (en) * 2003-10-06 2005-04-07 Purmal Andrei A. Method and composition for treating a biological sample
EP1838355B1 (en) 2004-10-29 2013-08-14 Cerus Corporation Improved quenching methods for red blood cell inactivation process
BRPI0911176B8 (pt) 2008-04-09 2021-05-25 Cerus Corp método de tratar uma composição de célula vermelha sanguínea, composição de célula vermelha sanguínea, e método de reduzir a desidratação em uma composição de célula vermelha sanguínea
BR112014029515A2 (pt) 2012-06-01 2017-07-25 Boehringer Ingelheim Vetmedica Gmbh vacina de vírus schmallenberg (sbv), métodos de produção e usos da mesma, virus schmallenberg, usos de seus antígenos e composição de matéria
US11473055B2 (en) 2015-11-01 2022-10-18 Glycobac, Llc Virus-free cell lines and methods for obtaining same
CA3022602A1 (en) 2016-05-10 2017-11-16 Najit Technologies, Inc. Inorganic polyatomic oxyanions for protecting against antigenic damage during pathogen inactivation for vaccine production
KR102198877B1 (ko) 2019-07-16 2021-01-05 정소영 블루 라이트 차단 필터
CN113322252A (zh) * 2020-12-28 2021-08-31 广州凯普医药科技有限公司 一种拭子样本保存液

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3492289A (en) * 1966-06-13 1970-01-27 Dow Chemical Co Polymers of alkylenimines
US4036952A (en) * 1973-02-24 1977-07-19 Bayer Aktiengesellschaft Ethyleneimine inactivated microorganisms
US4058599A (en) * 1973-02-24 1977-11-15 Bayer Aktiengesellschaft Ethyleneimine inactivated organisms
RU594771C (ru) * 1973-05-07 1993-07-07 Всесоюзный научно-исследовательский ящурный институт Средство дл инактивации вирусов при изготовлении противовирусных препаратов
US4841023A (en) * 1986-06-25 1989-06-20 New York Blood Center, Inc. Inactivation of viruses in labile protein-containing compositions using fatty acids
US5000951A (en) * 1987-03-09 1991-03-19 Diamond Scientific Company Multivalent canine distemper virus vaccine
US5055485A (en) * 1988-12-02 1991-10-08 New York Blood Center, Inc. Inactivation of viruses in cell- and protein-containing compositions using aryl diol epoxides
RU1768636C (ru) * 1989-08-16 1992-10-15 Всесоюзный научно-исследовательский ветеринарный институт птицеводства Способ получени антигена вируса болезни Гамборо
US5232844A (en) * 1990-05-15 1993-08-03 New York Blood Center Photodynamic inactivation of viruses in cell-containing compositions
US5120649A (en) * 1990-05-15 1992-06-09 New York Blood Center, Inc. Photodynamic inactivation of viruses in blood cell-containing compositions
US5565205A (en) * 1990-08-16 1996-10-15 Solvay Animal Health, Inc. Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
JPH05502183A (ja) * 1990-09-04 1993-04-22 シャンブロム,エドワード 血液、組織および生物体液の保存
GB9108682D0 (en) * 1991-04-23 1991-06-12 Wellcome Found Production of vaccines
FR2679253B1 (fr) * 1991-07-15 1994-09-02 Pasteur Institut Proteines de resistance a la cycloheximide. utilisation comme marqueur de selection par exemple pour controler le transfert d'acides nucleiques.
EP0612532A3 (en) * 1993-02-26 1998-02-04 Solvay Animal Health, Inc. Canine coronavirus vaccine from feline enteric coronavirus
EP0773716A4 (en) * 1995-06-07 1999-08-04 Cerus Corp TREATMENT OF RED BLOOD CELL SOLUTIONS WITH ANTIVRAL ACTIVE SUBSTANCES

Also Published As

Publication number Publication date
BR9610306A (pt) 1999-07-06
JP2003176238A (ja) 2003-06-24
WO1997007674A1 (en) 1997-03-06
IL123467A0 (en) 1998-09-24
EP0915648B1 (en) 2002-05-08
DK0915648T3 (da) 2002-08-26
EP0915648A4 (zh) 1999-05-19
NZ316787A (en) 1999-11-29
KR19990044303A (ko) 1999-06-25
US6114108A (en) 2000-09-05
ATE319483T1 (de) 2006-03-15
PL187759B1 (pl) 2004-10-29
EP0915648A1 (en) 1999-05-19
AU694892B2 (en) 1998-07-30
PT915648E (pt) 2002-09-30
JP2001520635A (ja) 2001-10-30
ATE217144T1 (de) 2002-05-15
AU6909996A (en) 1997-03-19
NO980881D0 (no) 1998-02-27
DE69621161T2 (de) 2002-11-21
HK1042254A1 (zh) 2002-08-09
DE69621161D1 (de) 2002-06-13
KR100486765B1 (ko) 2005-09-02
EP1129728A1 (en) 2001-09-05
EP1129728B1 (en) 2006-03-08
PL325338A1 (en) 1998-07-20
DE69635871D1 (de) 2006-05-04
CA2230671A1 (en) 1997-03-06
DE69635871T2 (de) 2007-05-24
ES2173314T3 (es) 2002-10-16

Similar Documents

Publication Publication Date Title
NO980881L (no) Fremgangsmater og blandinger for selektiv modifikasjon av nukleinsyrer
ES2563677T3 (es) Composiciones de combinaciones de Neisseria
ATE466932T1 (de) Vermehrung von viren in zellkultur
BR9808154A (pt) Moléculas de ácido nucléico codificando enzimas tendo atividade de frutosil polimerase
ATE482267T1 (de) Tierzellen und verfahren für die replikation von influenza viren
CA2232604A1 (fr) Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
DE60236864D1 (de) Chimere alphavirus-replikon-partikel
WO2001026682A3 (en) Modified plant viruses and methods of use thereof
ATE363530T1 (de) Enzymstabilisierung durch kationische, oberflächenaktive substanzen
CY1105109T1 (el) Διαδικασια για την παρασκευη μικρου μοριακου βαρους πολυαιθυλενιμινης
NO20004161L (no) Gruppe B streptokoccus antigener
EP1808180A3 (en) Modified GP 100 and uses thereof
NO952039L (no) Proteiner med glykosyltransferase-aktivitet
NO910982D0 (no) Uratoksydase-aktivt protein, rekombinant gen som koder for det, ekspresjonsvektor, mikroorganismer og transformerteceller.
ATE414146T1 (de) Methoden zur herstellung von helpervirusfreien präparationen von freien rekombinenten aav- vektoren mit hohem titer
NO983946D0 (no) Parapoksyviruser inneholdende fremmed DNA, fremstilling og anvendelse derav i vaksiner
ES2187504T3 (es) Vectores no oncovirales, basados en el vmmp, con encapsidacion defectuosa.
EP2336339A3 (en) Production of viral vectors
ATE284140T1 (de) Konservierung von zellen
DK0852623T3 (da) Nukleinsyremolekyler kodende for proteiner, som medierer adhæsionen af Neisseria-celler til humane celler
ATE479705T1 (de) Reduzierter slam abhängiger zell eintritt
DE60042922D1 (de) Virale expressionsvektoren für pflanzen
NO178870C (no) Fremgangsmåte for fremstilling av modifisert Eglin B eller C samt DNA, ekspresjonsvektor og vertsmikroorganisme
DK0952982T3 (da) Hidtil ukendte hepatitis B inhibitorer
PT870050E (pt) Virus que expressam proteinas toxicas e linhas de celulas produtoras

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application
FC2A Withdrawal, rejection or dismissal of laid open patent application